To better elucidate the possible role of GLCCI1 in COPD, our research then selected a well-characterized population of 204 Chinese clinical stable COPD patients, and all the patients received inhaled fluticasone propionate added salmeterol therapy for 24 weeks. The gene discussed is GLCCI1; the disease is chronic obstructive pulmonary disease.